Evidence map›Paper›PMID 21892670›Full record

ArticleInternational journal of clinical oncology2012

Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens.

Claudia Marchetti, Filippo Bellati, Angela Musella, Chiara Napoletano, Giorgia Perniola, Violante Di Donato, Sandro Pignata, Marianna Nuti, Pierluigi Benedetti Panici

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claudia MarchettiDepartment of Gynecology and Obstetrics, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Filippo Bellati
Angela Musella
Chiara Napoletano
Giorgia Perniola
Violante Di Donato
Sandro Pignata
Marianna Nuti
Pierluigi Benedetti Panici

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation.

Indexed as

Drug Administration ScheduleCA-125 AntigenCarboplatinDisease-Free SurvivalFemaleHumansMembrane ProteinsMiddle AgedNeoadjuvant TherapyNeoplasm StagingOvarian NeoplasmsPaclitaxelCA-125 AntigenCarboplatinMembrane ProteinsMUC16 protein, humanPaclitaxel

Identifiers

PMID21892670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.